Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin plc (NASDAQ:AMRN) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Total net revenue of $67.5 million, down 16% year-over-year
- Cash position of $307 million
- Net income of $1.5 million, or $0.00 per share
- Non-GAAP adjusted net income of $5.9 million, or $0.01 per share
- Completed CEO transition with Aaron Berg appointed as President and CEO
- Received regulatory approval for VASCEPA in China for cardiovascular risk reduction
- Secured national reimbursement for VAZKEPA in Portugal and Greece
- Delivered $50 million in annual savings from 2023 restructuring
The company faces challenges from generic competition in the U.S. but continues to focus on operational execution and expanding VASCEPA/VAZKEPA globally.
Amarin plc (NASDAQ:AMRN) has announced that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement. This approval is aimed at reducing cardiovascular event risks in adult statin-treated patients with high cardiovascular risk, elevated triglycerides, and established cardiovascular disease or diabetes with at least one other cardiovascular risk factor.
The reimbursement, effective August 1, 2024, marks the eighth national reimbursement of VAZKEPA® in Europe, where Amarin has intellectual property protection until 2039. This approval addresses a significant need in Portugal, where cardiovascular disease accounts for 29% of total mortality. Amarin's CEO, Aaron Berg, emphasized the importance of this new treatment option for Portuguese patients and physicians.
Amarin plc (NASDAQ:AMRN) has announced it will host a conference call on July 31, 2024, at 8:00 a.m. ET to discuss its second quarter 2024 financial results. The call will feature Aaron Berg, President & CEO, and other senior management team members. The financial results will be released pre-market on the same day.
To enhance shareholder engagement, Amarin is partnering with Say Technologies, allowing shareholders to submit and upvote questions from July 17th at 8:00 am ET until 24 hours before the call. Selected questions will be answered during the earnings call. Shareholders can submit questions at https://app.saytechnologies.com/amarin-2024-q2.
The conference call can be accessed through Amarin's website or by dialing in. A replay will be available after the call.
Amarin 's (NASDAQ:AMRN) partner, EddingPharm, has received regulatory approval for VASCEPA® (icosapent ethyl) from China's National Medical Products Administration (NMPA) for cardiovascular risk reduction. VASCEPA will now be used alongside statin therapy to reduce cardiovascular events in adults with elevated triglycerides (≥150 mg/dL) and other high-risk factors. EddingPharm is preparing for the National Reimbursement Drug Listing (NRDL) to enhance commercial launch across Mainland China. This approval is significant given China's high cardiovascular disease (CVD) burden, with 330 million patients and CVD accounting for up to 47% of deaths. VASCEPA's inclusion in the NRDL could ensure widespread access and reimbursement. Additionally, Amarin will receive a $15 million milestone payment and tiered double-digit royalties on net sales in China. However, EddingPharm must conduct a post-approval study to further validate VASCEPA's efficacy.
Amarin (NASDAQ:AMRN) has appointed Aaron Berg as the new President and CEO, effective immediately. Berg, previously Executive Vice President and President of the U.S. Business at Amarin, succeeds Patrick Holt, who is stepping down to pursue other opportunities. Berg brings over 30 years of biopharmaceutical industry experience, including significant roles at Kos Pharmaceuticals and Essentialis. His immediate focus will be on delivering value to investors and maximizing the potential of VASCEPA®/VAZKEPA for patients. This leadership change is expected to drive strategic initiatives and business growth for Amarin.
Amarin (NASDAQ:AMRN) has announced that the Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement. This decision allows high-risk cardiovascular patients treated with statins and having elevated triglycerides to access the drug. VAZKEPA® has now achieved national reimbursement in seven European countries.
To commercialize VAZKEPA® in Greece, Amarin has partnered with Vianex S.A., a leading pharmaceutical company in Greece. Vianex will be the exclusive distributor, handling the import, registration, distribution, and commercialization of the product. Amarin will supply the finished product to Vianex at a transfer price. The distribution will commence in the coming weeks.
Amarin's President & CEO, Patrick Holt, highlighted that this approval underscores the strength of their scientific data and the value VAZKEPA® offers to patients at risk of cardiovascular events. Christos Papadopoulos, Amarin’s Senior VP and Head of Commercial Europe, emphasized Vianex's strong commercial capabilities and expertise in cardiology, which align well with successfully bringing VAZKEPA® to Greek patients.
Amarin plc (NASDAQ: AMRN) will have their president and CEO, Patrick Holt, participate in a fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20th, 2024, in NYC. The session will be webcast live and archived on the Company’s website.
Amarin plc (NASDAQ:AMRN) reported its first-quarter 2024 business update and financial results. The company received a new patent extending intellectual property protection in Europe until 2039. While the U.S. market saw a decline in revenue due to generic competition, the European market experienced significant growth. Amarin also announced a share repurchase program and remains stable with a cash position of $308 million. Overall, the company is focused on enhancing its value for the future.
Summary not available.
Summary not available.